LabVantage Solutions Introduces Secure Web Portal with Version 8.7 of Its LabVantage LIMS Platform

LabVantage 8.7 Introduces Secure Web Portal The latest version of LabVantage LIMS (laboratory information management system) includes a redesigned web portal that lets LabVantage customers extend appropriate access rights to their clients outside the laboratory. The new Portal protects customers’ valuable and sensitive data, while eliminating the need for manual requests for tests and other services. A new, next-generation user interface makes Portal features easier than ever to use for those outside the lab needing access to data but who are not familiar with LIMS. LabVantage 8.7 Highlights: • A secure customer self-service web Portal for external clients of the lab, ensuring faster and more complete client-submitted requests and direct access to more meaningful information and data. • Customers’ choice of “apps” that deliver various functions, such as Portal account management, request submissions, status tracking and test-results viewing, and requests for test kits. • Simple and intuitive user experience with clean, cockpit-style screens that allow users to navigate safely, efficiently, and with little or no training. • Lab administrator self-support leveraging existing LabVantage knowledge of functions, configuration tools, and other skills. • Available immediately.

BOC Sciences Offers Pseudouridine and Its Derivatives to Promote mRNA Development

Volpi partners with TOPIC Embedded Systems to offer intelligence-embedded optical measurement

Volpi, a world leader in optoelectronics with operations in the U.S. and Switzerland, has partnered with Netherlands-based TOPIC Embedded Systems, a leader in embedded intelligence, to expand its portfolio of optoelectronic measurement solutions and further advance its digital initiatives.

Alfa Chemistry Diversifies Supply of Active Pharmaceutical Ingredients for Pharmaceutical Preparation

Alfa Chemistry Materials Announces a New Product Offering of Quantum Dots

LIQUID STABLE, MATRIX PLUS™ CHEMISTRY REFERENCE MATERIALS NOW OFFERED BY VERICHEM LABORATORIES

Verichem’s MATRIX PLUS™ Chemistry Reference Kit is expressly intended to support overall system QC and CLIA compliance within the clinical laboratory.

FDS Amplicare Awards $25,000 Grant to CPESN Minnesota to Help 50 Community Pharmacies Expand Healthcare Services

FDS Amplicare Awards $25,000 Grant to CPESN Minnesota to Help 50 Community Pharmacies Expand Healthcare Services

Protheragen MedAI Fully Supports In Vitro Pharmacology Research for Drug Discovery

Flywheel and HealthMyne Partner to Provide End-to-End Radiomic Data Management and Analysis

Flywheel and HealthMyne: Combined technology solution to accelerate radiomics research and clinical trial outcomes

Standigm Secures Strategic Investment from SK Chemicals for Expanding its AI-Drug Development Capacity

Standigm Inc. (“Standigm”), a leading workflow artificial intelligence (AI) drug discovery company, and SK Chemicals Co., Ltd (“SK Chemicals”), a life science and green chemicals company, announced today that they have signed a strategic partnership contract for collaboration regarding clinical development of Standigm’s AI-driven drug candidate for non-alcoholic steatohepatitis (“NASH”) and the foundation of Standigm’s Synthesis Research Center within the headquarters of SK Chemicals. This partnership was made in conjunction with SK Chemicals’ participation in Standigm’s pre-IPO round of fundraising.

New Cotiviti Research Captures Healthcare Payer Shift from Postpay to Prepay Claim Integrity

Survey of >100 health plan leaders offers insight into the challenges of balancing prospective and retrospective approaches across enterprise payment integrity programs

VERICHEM LABORATORIES EXPANDS LINE OF BIO-SYNTHETIC CLINICAL REFERENCE MATERIALS FOR URINE CHEMISTRIES

VERICHEM now offers clinical laboratorians an extensive line of liquid stable and ready-to-use biosynthetic clinical reference materials for urine chemistry assays.

Genezen breaks ground on cGMP lentiviral vector production facility

Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has broken ground on a new multiphase master plan for a 75,000+ square foot cGMP-compliant Lentiviral vector production facility.

ZEISS revolutionizes quantitative petrography

ZEISS introduces unique digitization system for virtual microscopy, collaboration and machine learning data analytics

Protheragen MedAI Offers Comprehensive Solutions for Drug Research and Development, Medical Imaging and Medical Therapy and Research System

BOC Sciences Completed Deployment of GMP Manufacturing Facilities to Promote Drug R&D

Shimmer Adopts the V3 Framework to Validate its Verisense® Wearable Sensing Platform for Clinical Trials

The Verisense IMU (inertial measurement unit) was the first Shimmer sensor validated following the V3 framework championed by the Digital Medicine Society (DiMe).

Samsung Biologics Issues Its First Annual Sustainability Report

Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company’s policies for an enhanced ESG management system and related plans. The report focuses on the company’s commitment to taking part in social responsibility over the past decade and its future plans for the next ten years and beyond.

Watson-Marlow Fluid Technology Group wins Best Business Award

Watson-Marlow Fluid Technology Group announces it has been named winner of the Best Employer category at the 2021 Best Business Awards.

BRIM Biotechnology’s lead candidate BRM421 for Dry Eye Syndrome shows promising results in Phase II clinical trials

BRIM Biotechnology, Inc. is pleased to advise that the Type C meeting with the US Food and Drug Administration (FDA) for the further development of lead candidate BRM421 for Dry Eye Syndrome (DES) has taken place, and preparation to initiate Phase III trials in 2022, is underway.